You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: January 5, 2025

Drug Price Trends for NDC 68180-0151


✉ Email this page to a colleague

« Back to Dashboard


Average Pharmacy Cost for 68180-0151

Drug Name NDC Price/Unit ($) Unit Date
MIRABEGRON ER 25 MG TABLET 68180-0151-06 9.88744 EACH 2024-12-18
MIRABEGRON ER 25 MG TABLET 68180-0151-09 9.88744 EACH 2024-12-18
MIRABEGRON ER 25 MG TABLET 68180-0151-09 8.67931 EACH 2024-11-20
MIRABEGRON ER 25 MG TABLET 68180-0151-06 8.67931 EACH 2024-11-20
MIRABEGRON ER 25 MG TABLET 68180-0151-09 10.80790 EACH 2024-10-23
MIRABEGRON ER 25 MG TABLET 68180-0151-06 10.80790 EACH 2024-10-23
>Drug Name >NDC >Price/Unit ($) >Unit >Date

Best Wholesale Price for NDC 68180-0151

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions
Drug Name Vendor NDC Count Price ($) Price/Unit ($) Dates Price Type
>Drug Name >Vendor >NDC >Count >Price ($) >Price/Unit ($) >Dates >Price Type
Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

68180-0151 Market Analysis and Financial Projection

Market Analysis and Price Projections for Drug NDC: 68180-0151

Introduction to NDC 68180-0151

The National Drug Code (NDC) 68180-0151 identifies a specific pharmaceutical product, but for the purpose of this analysis, we will focus on a similar product category to provide relevant market insights and price projections.

Understanding the Pharmaceutical Market

The pharmaceutical market is complex and influenced by various factors, including regulatory oversight, supply chain dynamics, and technological advancements.

Regulatory Oversight

Regulatory bodies play a crucial role in monitoring drug prices and ensuring transparency. For instance, the Oregon Drug Price Transparency Program requires manufacturers to report price increases and new high-cost drugs, helping to understand the factors influencing drug prices[2].

Supply Chain Dynamics

The pharmaceutical supply chain involves multiple entities, including manufacturers, pharmacy benefit managers (PBMs), and health insurers. Each entity can impact the final cost of the drug to consumers. For example, PBMs are required to register with state authorities and report on rebates, which can affect drug pricing[2].

Current Market Trends

Drug Price Inflation

Vizient Inc. projects a 3.8% increase in drug prices for 2024, driven largely by specialty pharmaceuticals. This trend is expected to continue into 2025, with a focus on gene therapies and other advanced treatments[3].

Specialty Pharmaceuticals

Specialty drugs, which treat complex or chronic conditions, are a significant driver of pharmacy spend. These drugs, including those for cancer, infectious diseases, and autoimmune conditions, are expected to see a 4.18% price increase in 2024[3].

Biosimilars

Biosimilars, which are biologic products that are highly similar to an already-approved biologic product, are expected to grow in market share. However, their price increase is projected to be minimal at 0.55%[3].

Price Projections for Similar Drug Categories

Given the lack of specific data on NDC 68180-0151, we can infer price projections from similar drug categories.

Generic Drugs

Generic drugs, like the one recalled by Lupin Pharmaceuticals (though not the exact NDC), can experience significant price fluctuations. For example, a generic naproxen saw a 2,527% price increase between 2012 and 2021[2].

Specialty and Generic Drug Price Increases

For specialty drugs, the projected increase is around 4.18% for 2024. For generic drugs, the median price increase reported in 2022 was 19.9%[2][3].

Factors Influencing Drug Prices

Manufacturing and Quality Control

Recalls due to impurities, such as the one initiated by Lupin Pharmaceuticals for Irbesartan Tablets, can impact pricing and availability. Ensuring quality control is crucial for maintaining stable prices[1].

Market Dynamics and Utilization

The increasing utilization of certain drugs, such as weight loss medications and gene therapies, drives up costs. Gene therapies, in particular, are expected to see significant price increases due to their complexity and rarity[5].

Regulatory and Legislative Actions

Legislative actions, such as the implementation of upper payment limits or price negotiation authorities, can influence drug prices. For example, the Inflation Reduction Act of 2022 introduced price negotiation for Medicare, which could set a precedent for other states[2].

Key Takeaways

  • Regulatory Oversight: Transparency programs and regulatory actions are crucial for understanding and managing drug prices.
  • Supply Chain Dynamics: Multiple entities in the supply chain, including PBMs and health insurers, impact drug costs.
  • Market Trends: Specialty pharmaceuticals and gene therapies are driving price increases.
  • Biosimilars: Expected to grow in market share with minimal price increases.
  • Quality Control: Ensuring drug quality is essential for stable pricing.

FAQs

  1. What is the National Drug Code (NDC)?

    • The NDC is a unique, three-segment number used to identify drug products and ensure their safety and effectiveness[4].
  2. Why are drug prices increasing?

    • Drug prices are increasing due to various factors, including the rise of specialty pharmaceuticals, gene therapies, and market dynamics such as increased utilization and regulatory changes[3][5].
  3. How do biosimilars impact drug prices?

    • Biosimilars are expected to increase in market share but with minimal price increases, potentially offering more affordable alternatives to biologic drugs[3].
  4. What role do pharmacy benefit managers (PBMs) play in drug pricing?

    • PBMs influence drug prices through their formulary strategies and rebate reporting, which can affect the final cost to consumers[2].
  5. How can regulatory actions impact drug prices?

    • Regulatory actions, such as implementing upper payment limits or price negotiation authorities, can significantly influence drug prices and affordability[2].

Sources

  1. Lupin Pharmaceuticals Inc. Recall Notice - California State Board of Pharmacy.
  2. Oregon Drug Price Transparency Program Annual Report 2022 - Oregon Department of Consumer and Business Services.
  3. Vizient Projects 3.8% Drug Price Increase Driven by Specialty Pharmaceuticals - Vizient Inc.
  4. National Drug Code Database Background Information - FDA.
  5. Pharmacy Market Outlook Summer 2024 - Vizient Inc.

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.